371 results for "Neuroplasticity"
Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics
ACS Chemical Neuroscience – October 13, 2025
Summary
A novel compound, zalsupindole, effectively regrows brain connections linked to depression without inducing hallucinations, a significant step in **Psychedelics and Drug Studies**. Developed through **Chemical synthesis and alkaloids**, this agent demonstrated robust neuroplasticity and sustained antidepressant-like effects in rats. Its impact was comparable to or greater than ketamine, psilocybin, and N,N-dimethyltryptamine. This highlights the profound **Neurotransmitter Receptor Influence on Behavior**, suggesting zalsupindole could offer a safer, scalable treatment for conditions like depression, overcoming the limitations of traditional psychedelic compounds.
Abstract
Many neuropsychiatric conditions, including depression, involve synaptic loss and atrophy of the prefrontal cortex. The rapid regrowth of cortical ...
Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.
Psychopharmacology – July 04, 2024
Summary
Psilocybin shows remarkable promise in treating stubborn depression by boosting brain plasticity and social behavior. In a groundbreaking discovery, researchers found that a single dose significantly improved social interaction and mood in both treatment-resistant and healthy rats. The compound triggered positive changes in key brain proteins BDNF and Arc, suggesting it helps rewire neural circuits for lasting therapeutic benefits.
Abstract
Our study aimed to unravel the unknown mechanisms behind the exceptional efficacy of Psilocybin (PSI) in treating treatment-resistant depression (T...
205. SYNERGISTIC BEHAVIORAL AND NEUROPLASTIC EFFECTS OF PSILOCYBIN-NMDAR MODULATOR ADMINISTRATION
The International Journal of Neuropsychopharmacology – August 01, 2025
Summary
Combining the psychedelic alkaloid Psilocybin with specific NMDA receptor modulators significantly reduced its hallucinogenic effects in preclinical models. This advance in Neuroscience and Drug Studies suggests a new path for safer therapeutic applications in Psychology. These chemical combinations not only mitigated adverse reactions but also enhanced brain Neuroplasticity, particularly in areas like the hippocampus. This approach could optimize the therapeutic potential of psychedelics, making them more accessible for treating neuropsychiatric disorders by fine-tuning their effects.
Abstract
Abstract Background The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and...
Premorbid Characteristics of the SAPAP3-Mouse Model of Obsessive-Compulsive Disorder: Behavior, Neuroplasticity, and Psilocybin Treatment
OpenAlex – September 23, 2024
Summary
Juvenile mice modeling obsessive-compulsive disorder (OCD) display significant anxiety, spending less time in open maze arms, *before* developing compulsive behaviors. This parallels human Obsessive-Compulsive Spectrum Disorders. Psychology and Neuroscience observations showed Psilocybin (4.4 mg/kg), a focus in Psychedelics and Drug Studies, did not alleviate this early anxiety. However, adult male mice modeling OCD showed increased neuroplasticity-related proteins like GAP43 and synaptophysin in emotion-regulating brain regions, unlike their juvenile counterparts. This highlights age-dependent brain changes relevant for psychotherapist-led early interventions.
Abstract
Abstract Background SAPAP3-knockout (KO) mice develop excessive self-grooming behavior at 4-6 months of age, serving as a model for obsessive-compu...
Psilocybin promotes neuroplasticity and induces rapid and sustained antidepressant-like effects in mice
Journal of Psychopharmacology – April 28, 2024
Summary
A single dose of psilocybin rapidly and lastingly alleviated behavioural despair in mice, a compelling finding for neuroscience and psychology. This pharmacology research, relevant to psychedelics and drug studies, reveals psilocybin promotes neuroplasticity in the hippocampus and prefrontal cortex. It enhanced synaptic plasticity markers, including Synapsin I levels and dendritic branching, reversing stress-induced deficits. This suggests its influence on neurotransmitter receptors, offering a novel antidepressant approach for conditions like tryptophan-related brain disorders.
Abstract
Background: Psilocybin offers new hope for treating mood disorders due to its rapid and sustained antidepressant effects, as standard medications r...
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models
Neuroscience & Biobehavioral Reviews – April 04, 2025
Summary
Psychedelics offer rapid, enduring therapeutic effects by profoundly enhancing brain neuroplasticity. Neuroscience reveals these compounds, including classic and non-classic varieties, modulate neural pathways. Preclinical drug studies demonstrate they heighten brain sensitivity and re-open developmental windows for structural changes, impacting mood and behavior. This mechanism, involving neurotransmitter receptor influence, holds significant promise in Psychology for neuropsychiatric conditions. While human translation faces imaging challenges, understanding these findings guides targeted interventions and advances their therapeutic potential.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
arXiv Preprint Archive – November 29, 2024
Summary
Psychedelics like LSD and psilocybin can rewire brain connections after just one dose, unlike traditional psychiatric medications. These compounds boost the brain's natural plasticity, helping neurons form new pathways and adapt to change. Studies show they create a window of enhanced learning and adaptation, leading to lasting improvements in mood and behavior.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models
arXiv (Cornell University) – November 29, 2024
Summary
Psychedelics demonstrate remarkable potential for rapid, lasting treatment of neuropsychiatric conditions. Neuroscience reveals these compounds, often natural alkaloids or products of chemical synthesis, profoundly enhance brain neuroplasticity—the nervous system's adaptive capacity. Preclinical and clinical drug studies indicate they re-open developmental windows, driving structural and functional changes that significantly impact mood and behavior. This critical effect, vital for psychology and cognitive science, is being elucidated in humans using advanced techniques, including isotopic radioligands, paving the way for targeted interventions.
Abstract
Neuroplasticity, the ability of the nervous system to adapt throughout an organism's lifespan, offers potential as both a biomarker and treatment t...
Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration
Translational Psychiatry – June 13, 2025
Summary
Combining psilocybin, a potent hallucinogen, with NMDA receptor modulators significantly reduces adverse effects while boosting brain neuroplasticity. In ICR male mice, psilocybin's hallucinogenic-like effects were dose-dependently decreased by D-serine or D-cycloserine. This pharmacology approach also modeled antipsychotic benefits for conditions like schizophrenia. Neuroscience shows these chemical combinations enhanced synaptic protein expression across four brain regions, including the hippocampus. This breakthrough in Medicine and Psychedelics and Drug Studies suggests psychotherapists could utilize optimized psilocybin formulations, influencing neurotransmitter receptor behavior for Psychology applications.
Abstract
The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophrenia, is l...
Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects
Quality in Sport – January 31, 2026
Summary
Psilocybin-assisted psychological intervention rapidly reduces depressive symptoms, with effects lasting six months in some treatment-resistant depression protocols. This compelling finding in clinical psychology highlights a key neuroscience mechanism: neuroplasticity. Serotonergic activation leads to structural synaptic remodeling, observed in preclinical work and human functional neuroimaging. This biological mechanism, supported by studies on extinction learning relevant to exposure therapy, suggests how psychedelics exert their antidepressant effects. The medicine offers a promising avenue for sustained improvement, linking transient drug effects to enduring psychological change.
Abstract
Psilocybin-assisted interventions have shown rapid reductions in depressive symptoms in controlled clinical settings, raising questions about biolo...
Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration
OpenAlex – November 28, 2024
Summary
Combining psilocybin, a potent alkaloid, with NMDA receptor modulators can enhance its therapeutic potential and mitigate adverse effects. In ICR male mice, psilocybin-induced head twitches were dose-dependently reduced. Neuroscience in Psychedelics and Drug Studies also revealed increased neuroplasticity: psilocybin-D-serine boosted GAP43 across all 4 brain regions; psilocybin-D-cycloserine elevated PSD95 across all 4. This strategy, influencing neurotransmitter receptors, offers a safer path for psychology, optimizing treatment.
Abstract
Abstract The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophre...
Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signaling.
International immunopharmacology – June 26, 2025
Summary
Magic mushroom compounds psilocybin and psilocin show remarkable ability to reduce brain inflammation and promote healing. These substances work through specific brain receptors to calm overactive immune cells (microglia) while boosting BDNF, a protein that helps brain cells grow and form new connections. This dual action suggests promising therapeutic potential for various neurological conditions.
Abstract
Psilocybin, a serotonergic psychedelic, has demonstrated therapeutic potential in neuropsychiatric disorders. While its neuroplastic and immunomodu...
LSD Modulates Proteins Involved in Cell Proteostasis, Energy Metabolism and Neuroplasticity in Human Cerebral Organoids.
ACS omega – August 27, 2024
Summary
LSD's effects on the brain may extend beyond consciousness alteration - new research shows it influences fundamental cellular processes in lab-grown brain tissue. The drug impacts proteins involved in energy production, cellular maintenance, and the brain's ability to form new connections. These changes could explain how psychedelics potentially help treat mental health conditions.
Abstract
Proteomic analysis of human cerebral organoids may reveal how psychedelics regulate biological processes, shedding light on drug-induced changes in...
Premorbid characteristics of the SAPAP3 mouse model of obsessive-compulsive disorder: behavior, neuroplasticity, and psilocybin treatment
The International Journal of Neuropsychopharmacology – March 29, 2025
Summary
Juvenile mice modeling Obsessive-Compulsive Spectrum Disorders display significant anxiety *before* grooming behaviors, informing Psychology. Using open field and elevated plus maze tests, these juvenile animals showed anxiety. Psilocybin (4.4 mg/kg) did not alleviate this, a key insight for Psychedelics and Drug Studies and Neurotransmitter Receptor Influence on Behavior. Neuroscience reveals that while adult mice exhibited increased Synaptophysin and Gap-43 protein in the Hippocampus and Amygdala, reflecting synaptic plasticity and neuroplasticity, juvenile brains did not. SAPAP3 is a postsynaptic density scaffold protein, suggesting age-dependent adaptations.
Abstract
Abstract Background SAPAP3-knockout (SAPAP3-KO) mice develop excessive self-grooming behavior at 4-6 months of age, serving as a model for obsessiv...
Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor.
Pharmaceuticals (Basel, Switzerland) – January 24, 2025
Summary
Scientists have discovered a breakthrough in depression treatment: a new class of drugs called Stinels that work faster and more safely than traditional antidepressants. Unlike ketamine, which blocks brain receptors and can cause dissociative effects, Stinels gently enhance receptor activity through positive modulation, promoting healthy brain plasticity without serious side effects.
Abstract
Plastogens are a class of therapeutics that function by rapidly promoting changes in neuroplasticity. A notable example, ketamine, is receiving gre...
Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.
Molecular psychiatry – December 01, 2024
Summary
Depression involves more than just low serotonin levels - it's linked to reduced flexibility in brain circuits that process emotions and thoughts. Like a path that becomes deeply worn from constant use, negative thinking patterns can become "stuck." Treatments work by promoting brain plasticity, helping create new neural pathways. This explains why diverse approaches - from traditional antidepressants to therapy to newer options like ketamine - can effectively treat depression by helping the brain adapt and form healthier patterns.
Abstract
The serotonin deficit hypothesis explanation for major depressive disorder (MDD) has persisted among clinicians and the general public alike despit...
Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric Therapeutics
ACS Medicinal Chemistry Letters – December 16, 2025
Summary
A groundbreaking blood-based gene-expression diagnostic targeting FOXG1 offers objective detection of PTSD, enhancing precision medicine efforts. In a sample of 150 individuals, this method shows promise for scalability in neuropsychiatric therapeutics. Additionally, benzocyclobutenyl-methylamine modulators effectively normalize neuronal hyperexcitability, while templated-carrier sublingual 5-MeO-DMT formulations provide controlled neuroplasticity without hallucinations. These innovations collectively bridge molecular diagnostics and targeted circuit modulation, paving the way for advanced digital mental health interventions and transformative treatments in neuroscience and computational biology.
Abstract
New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 fo...
Toward Translatable Biomarkers of Psychedelic-Induced Neuroplasticity.
The American journal of psychiatry – January 01, 2025
Summary
Psychedelics like ketamine may literally help the brain grow new connections. Scientists have identified a key protein called SV2A that could serve as a biological marker for measuring how these compounds promote neuroplasticity - the brain's ability to rewire itself. This breakthrough enables tracking of how psychedelic medicines reshape neural networks, potentially revolutionizing mental health treatment.
Abstract
Numerous preclinical studies have demonstrated that psychedelics promote the growth of cortical neurons in the prefrontal cortex. However, measurin...
Understanding Neuroplasticity Induced by Tryptamines (UNITy): Understanding Neuroplasticity Induced by Tryptamines: Rewiring Maladaptive Memories in Hazardous Drinking with Memory Reactivation and Dimethyltryptamine (DMT)
Open Science Framework – October 20, 2025
Summary
DMT may significantly alter drinking behaviors in individuals with mild Alcohol Use Disorder (AUD). In a study involving up to 120 participants, groups received either DMT or placebo alongside memory retrieval tasks. Over nine months, researchers will track changes in drinking levels through various methods, including blood tests and cognitive assessments. By exploring the effects of DMT on memory reconsolidation, this comprehensive approach aims to uncover lasting changes in cognition and mood, potentially offering new insights into addiction treatment through neuroscience and psychology.
Abstract
This study examines the existence and mechanistic underpinnings of lasting neural, cognitive, and behavioural plasticity in response to N-N-dimethy...
Towards an understanding of psychedelic-induced neuroplasticity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Psychedelics like LSD and psilocybin can rewire the brain's neural connections, particularly in areas controlling mood and memory. These substances trigger rapid growth of new neural connections and enhance brain plasticity, especially in the prefrontal cortex and hippocampus. This helps explain why a single treatment can lead to lasting positive changes in depression and anxiety that persist for months.
Abstract
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and add...
Neuroplasticity: Pathophysiology and Role in Major Depressive Disorder.
Critical reviews in oncogenesis – January 01, 2024
Summary
The brain's remarkable ability to rewire itself holds the key to understanding depression. When our brain's natural plasticity is disrupted, it can trigger a cycle where depression alters brain structure, which further deepens depressive symptoms. New research shows how certain brain chemicals and medications work by restoring healthy plasticity patterns, offering hope for better treatments. Antidepressants and ketamine therapy appear particularly effective at helping the brain rebuild crucial neural connections.
Abstract
Neuroplasticity is characterized by the brain's ability to change its activity in response to extrinsic and intrinsic factors and is thought to be ...
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity
Chinese Medical Journal – March 30, 2023
Summary
A single dose of psilocybin (2.5 mg/kg) rapidly and durably reduced fear responses in mice for up to seven days. This neuroscience finding suggests psychedelics could revolutionize cognitive psychology and psychotherapist approaches to PTSD. Psilocybin facilitates fear extinction by promoting neuroplasticity within the hippocampal formation. This alkaloid, studied in chemical synthesis and drug studies, influences neurotransmitter receptors, rescuing reductions in hippocampal dendritic complexity and neurogenesis. This powerful effect on brain structure offers a promising avenue for medicine.
Abstract
Abstract Background: Posttraumatic stress disorder (PTSD) and depression are highly comorbid. Psilocybin exerts substantial therapeutic effects on ...
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity.
Chinese medical journal – December 20, 2023
Summary
A single dose of psilocybin helped mice overcome fear responses by promoting brain adaptability. The compound enhanced memory-related brain changes and reduced fear behaviors both immediately and a week later. These findings suggest psilocybin could potentially help treat trauma-related conditions by making the brain more receptive to positive change during therapy.
Abstract
Posttraumatic stress disorder (PTSD) and depression are highly comorbid. Psilocybin exerts substantial therapeutic effects on depression by promoti...
Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics
Frontiers in Psychiatry – September 10, 2021
Summary
Psychedelics like psilocybin and LSD show remarkable therapeutic potential for stress-related disorders, offering antidepressant, anxiolytic, and cognitive benefits. Neuroscience indicates these drug studies influence brain neuroplasticity. Analysis of 20 studies, including 4 clinical ones, reveals single doses rapidly alter molecular and cellular plasticity. Repeated administration stimulated neurogenesis and increased plasticity-related proteins for up to a month. This suggests psychedelics profoundly impact brain function, potentially through neurotransmitter receptor influence, offering new avenues in psychology for treating brain disorders.
Abstract
Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psilocybin, and LSD, in stress-related disorders. The...
Novel treatments for anorexia nervosa: Insights from neuroplasticity research
European Eating Disorders Review – October 12, 2023
Summary
Deficiencies in brain neuroplasticity are central to Anorexia nervosa, a severe eating disorder. This compelling insight from clinical psychology and psychiatry is reshaping mental health research topics. Psychotherapists and medical professionals are exploring novel treatments for anorexia. These include psychopharmacological agents like ketamine or psilocybin, alongside psychotherapeutic strategies like imagery rescripting and yoga. Addressing neuroplasticity offers promising avenues for improving Eating Disorders and Behaviors, moving beyond traditional diet and metabolism studies. Future investigations will require large sample sizes to confirm these pathways.
Abstract
Abstract Objective Treatment for anorexia nervosa (AN) remains challenging; there are no approved psychopharmacological interventions and psychothe...
S-ketamine alleviates depression-like behavior and hippocampal neuroplasticity in the offspring of mice that experience prenatal stress.
Scientific reports – November 06, 2024
Summary
Stress during pregnancy can significantly impact a child's mental health. New findings show that S-ketamine effectively treats depression in offspring exposed to prenatal stress by enhancing brain adaptability. The drug works by improving neuroplasticity in the hippocampus, a key brain region for emotional regulation, reversing stress-induced changes and boosting vital growth factors for healthy brain function.
Abstract
Prenatal stress exerts long-term impact on neurodevelopment in the offspring, with consequences such as increasing the offspring's risk of depressi...
Shared effects of electroconvulsive shocks and ketamine on neuroplasticity: A systematic review of animal models of depression.
Neuroscience and biobehavioral reviews – September 01, 2024
Summary
Both ketamine and electroconvulsive therapy show remarkable success in treating severe depression by boosting brain plasticity. These treatments increase BDNF protein levels and stimulate new neuron growth in the hippocampus. The treatments enhance brain cell connections and improve neurotransmitter function, suggesting they work through similar mechanisms to rapidly lift depression symptoms.
Abstract
Electroconvulsive shocks (ECS) and ketamine are antidepressant treatments with a relatively fast onset of therapeutic effects compared to conventio...
Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges
Advanced Neurology – December 04, 2025
Summary
Psychedelics like psilocybin and ketamine show remarkable potential in enhancing neuroplasticity, crucial for treating neuropsychiatric disorders. In clinical settings, 60-80% of participants with depression or PTSD reported significant symptom relief when these substances were combined with psychotherapy. These compounds primarily interact with serotonergic and glutamatergic systems, promoting rapid synaptogenesis and changes in brain connectivity. However, challenges regarding safety and the translation of findings into clinical practice remain. Addressing ethical and legal issues is essential for integrating these therapies into modern psychiatric care.
Abstract
Psychedelics are gaining recognition for their effectiveness as modulators of neuroplasticity in the treatment of a range of neuropsychiatric disor...
Mushroom bioactives—polysaccharides to psilocybin: a viewpoint on the therapeutic use of mushrooms for consumers and patients for health and neuroplasticity
Translational Food Sciences – January 01, 2025
Summary
Psilocybin-containing mushrooms show compelling potential to aid trauma and foster neuroplasticity, sparking renewed interest in complementary and alternative medicine studies. Beyond traditional health-promoting compounds, the chemical synthesis and alkaloids of psychedelics are being re-evaluated for therapeutic use. Psychology professionals are exploring psilocybin as a medicine, questioning its regulated role in health management. This debate asks if these mushroom-derived compounds should be integrated into mainstream medicine, considering necessary safeguards for such drug studies.
Abstract
Abstract The use of mushrooms in health-promoting foods and substances is widely studied. There are compelling data to indicate that polysaccharide...
An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice
Journal of Psychopharmacology – January 06, 2026
Summary
Psilocybin, a potent hallucinogen, offers rapid antidepressant effects. Neuroscience reveals this medicine's pharmacology involves dose-dependent 5-HT2A receptor occupancy (RO₅₀ = 0.88 mg/kg). In mice, a 3 mg/kg dose reduced immobility in a behavioural despair test 24 hours later, while 1.5 mg/kg showed anxiolytic-like effects. Peak acute effects occurred between 44% and 62% receptor occupancy. These psychedelics enhance neuroplasticity, specifically synaptic plasticity, in the prefrontal cortex, not the amygdala. This suggests psilocybin's therapeutic psychology benefits stem from region-specific neuronal rewiring, influencing behavior.
Abstract
Background: Psilocybin has shown rapid and sustained antidepressant effects in patients with major depressive disorder, yet the neurobiological mec...
Neuroprotective Role of Ketamine in Reducing Neuroinflammation and Enhancing Neuroplasticity Against a Cortisol-Induced In Vitro Stress Model.
Molecular neurobiology – June 05, 2025
Summary
Groundbreaking research reveals how ketamine protects brain cells from stress-induced damage. High cortisol levels from chronic stress can trigger inflammation and harm neural connections. However, ketamine was found to shield neurons by blocking inflammatory signals (NF-κB and NLRP3), while boosting BDNF - a key protein that helps brain cells grow and form new connections. This explains ketamine's rapid antidepressant effects.
Abstract
Stress is widely recognized as a major environmental factor contributing to the development of mood disorders. In patients with Major Depressive Di...
Bioactive ketamine metabolite exerts in vivo neuroplastogenic effects to improve hippocampal function in a treatment-resistant depression model.
Cell reports – May 21, 2025
Summary
A ketamine metabolite shows promise in treating stubborn depression by rewiring brain circuits. Scientists found this compound restores memory and learning abilities in depression-prone rats by strengthening connections between brain cells. The metabolite enhanced hippocampal function - a brain region vital for memory - and improved how neurons communicate, leading to better cognitive performance and novelty recognition in previously treatment-resistant subjects.
Abstract
An acute increase in excitatory synaptic transmission contributes to the rapid antidepressant actions of neuroplastogens, including ketamine and it...
Neuroplasticity of directed connectivity in long-term meditation: Evidence from EEG Granger causality
bioRxiv – July 07, 2025
Summary
Remarkably, long-term meditation practice can profoundly reshape how different parts of your brain communicate. Researchers explored if extensive meditation changes these brain communication pathways. Using advanced brainwave recordings, they examined how signals flow between brain regions in experienced meditators versus non-meditators. Positive results revealed that long-term practitioners developed enhanced, more efficient neural connectivity. This strongly suggests that sustained meditation actively promotes beneficial brain reorganization, showcasing the brain's impressive neuroplasticity.
Abstract
Neuroplasticity of directed connectivity in long-term meditation: Evidence from EEG Granger causality
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.
Front Psychiatry – September 01, 2025
Summary
The brain's remarkable capacity to adapt and change is vital for mental well-being. Psychedelic therapy appears to harness this neuroplasticity, facilitating profound shifts in perception and thought. By exploring how these unique subjective experiences link to brain flexibility, positive clinical outcomes emerge. This offers a powerful avenue for improving mental health, promoting lasting therapeutic benefits.
Abstract
Psychedelic therapy: bridging neuroplasticity, phenomenology, and clinical outcomes.
Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization.
Front Psychiatry – April 08, 2025
Summary
Psychedelic therapy's success may depend more on therapeutic support than previously thought. New findings show that psychedelic compounds work best when combined with professional psychotherapy, enhancing the brain's natural ability to form new neural connections. This integrated approach helps patients process experiences and create lasting positive changes in thought patterns and behavior.
Abstract
Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization.
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Neuropsychiatric Disease and Treatment – January 01, 2025
Summary
Psilocybin, a potent hallucinogen and naturally occurring alkaloid, presents compelling promise in Medicine for Psychiatry. Its unique pharmacology, influencing neurotransmitter receptors, combats neuroinflammation and boosts neuroplasticity—factors underlying many mental health disorders. Neuroscience in Psychedelics and Drug Studies shows that supervised use with a psychotherapist provides benefits for depression and anxiety. Even sub-hallucinogenic microdoses demonstrate similar mood improvements, suggesting a more accessible alternative.
Abstract
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation ...
Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons
OpenAlex – June 07, 2024
Summary
Psilocin, psilocybin's active form, dramatically enhances neuroplasticity in human cortical neurons derived from stem cells. Neuroscience reveals it reshapes neural dynamics and brain function, potentially explaining its psychological benefits. Psilocin decreased surface 5-HT2A receptors, boosted BDNF, and altered gene expression, priming neurons for change. Morphologically, these cortical neurons became more complex with increased synaptic proteins, showing heightened excitability and network activity. This suggests psilocin induces a state of enhanced brain adaptability, crucial for treating conditions linked to synaptic dysfunction.
Abstract
Abstract Psilocybin is studied as innovative medication in anxiety, substance abuse and treatment-resistant depression. Animal studies show that ps...
Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Psychoactives – September 02, 2025
Summary
Compelling Neuroscience explores how psychedelics, including specific alkaloids like psilocybin derived through chemical synthesis, show significant potential in Medicine for addressing Dementia. This progressive neurodegenerative disease causes severe cognitive decline. Psychology and Drug Studies indicate these compounds might foster neuroplasticity, reduce neuroinflammation, and enhance cognitive flexibility. Such effects could slow disease progression and improve patient quality of life, suggesting new avenues for prevention by bolstering brain health.
Abstract
Dementia is a progressive neurodegenerative disease which is characterised by cognitive decline, memory loss, and behavioural changes. Patients suf...
MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst?
Translation The University of Toledo Journal of Medical Sciences – February 17, 2026
Summary
MDMA-assisted psychotherapy shows significant promise for treating PTSD, especially in patients resistant to traditional therapies. Clinical trials indicate up to 67% of participants experience lasting symptom relief. The treatment appears to reduce amygdala activity and enhance hippocampal connectivity, promoting neuroplasticity. Additionally, MDMA's prosocial effects improve therapeutic relationships, crucial for effective outcomes. This dual-action model suggests that MDMA not only aids cognitive processing but also fosters emotional safety, enhancing interpersonal communication during therapy. Such insights could refine protocols and therapist training in psychedelic-assisted approaches.
Abstract
MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsiv...
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.
Neuropsychiatric disease and treatment – January 01, 2025
Summary
Regular microdoses of psilocybin, the compound found in certain mushrooms, may help combat anxiety and depression by reducing brain inflammation and boosting neural connections. The active component, psilocin, works as both an anti-inflammatory agent and mood enhancer. Studies show that even small, non-hallucinogenic doses can effectively improve mental health symptoms and reduce neuroinflammation.
Abstract
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation ...
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.
Mol Med – December 19, 2024
Summary
Psychedelics like psilocybin and LSD don't just alter consciousness - they actually help the brain form new neural connections. A comprehensive analysis of multiple studies reveals these substances promote the growth of new brain cells and enhance the brain's ability to rewire itself, particularly in regions linked to mood and memory. This could explain their emerging potential in treating depression and PTSD.
Abstract
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.
Detecting neuroplastic effects induced by ketamine in healthy human subjects: a multimodal approach
bioRxiv Preprint Server – May 01, 2025
Summary
A single ketamine dose can significantly elevate glutamate levels in brain regions vital for mood regulation. Researchers used advanced imaging to show how this compound reorganizes brain activity and connections. They found increased integration between different brain networks, with a key hub playing a central role in reshaping brain hierarchies. These findings offer promising insights into its therapeutic potential.
Abstract
We investigated ketamine’s neuroplastic effects in healthy human subjects using integrated Positron Emission Tomography (PET)/Magnetic Resonance Im...
Assessing brain neuroplasticity: Surface morphometric analysis of cortical changes induced by Quadrato motor training.
Journal of anatomy – May 01, 2025
Summary
No Summary
Abstract
Morphological markers for brain plasticity are still lacking and their findings are challenged by the extreme variability of cortical brain surface...
Integrated Advancements in Neuroplasticity, Psychedelic Therapeutics, and AI-Driven Innovations for Precision Medicine.
ACS medicinal chemistry letters – April 10, 2025
Summary
No Summary
Abstract
Recent advancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms mark a ...
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Trends in Pharmacological Sciences – September 24, 2021
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Pharmacological Reviews – December 16, 2020
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling
Progress in Neuro-Psychopharmacology and Biological Psychiatry – June 28, 2022
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Emerging mechanisms of psilocybin-induced neuroplasticity
Trends in Pharmacological Sciences – September 16, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Ayahuasca, a psychedelic beverage, modulates neuroplasticity induced by ethanol in mice
Behavioural Brain Research – August 23, 2021
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies
Biological Psychiatry – February 01, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity
OPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg – January 01, 2026
Summary
Serotonergic psychedelics like LSD, psilocin, and DMT significantly inhibit neurotransmission, with notable effects on neuronal network activity. In a study using primary rat cortical cultures, psychedelics decreased synaptic vesicle fusion by up to 30% after 3-30 minutes of treatment. While DMT and psilocin enhanced responses at glutamatergic synapses, LSD and psilocin reduced presynaptic calcium transients. Additionally, LSD and DMT inhibited spontaneous neuronal firing without altering evoked responses. These findings deepen our understanding of how psychedelics could inform treatments for neuropsychiatric conditions.
Abstract
INTRODUCTION: Sertonergic psychedelics LSD, psilocin and DMT, have been shown to hold a great potential for treatment of various neuropsychiatric c...
Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions.
Journal of psychopharmacology (Oxford, England) – March 01, 2023
Summary
No Summary
Abstract
Numerous new agents with rapid onset antidepressant effects are entering clinical trials and clinical practice. Studies focus on either first-line ...
N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data.
Progress in neuro-psychopharmacology & biological psychiatry – March 20, 2025
Summary
DMT, a naturally occurring compound in the brain, plays a fascinating dual role in both stress response and brain development. Research reveals this molecule binds to specific receptors in the Golgi apparatus of brain cells, promoting neuroplasticity and healthy neurodevelopment. When stress occurs, DMT levels increase naturally, suggesting it acts as part of the body's adaptive response system. These findings explain how DMT influences brain function and may contribute to therapeutic benefits.
Abstract
Renewed interest in the clinical use of psychedelic drugs acknowledges their therapeutic effectiveness. It has also provided a changing frame of re...
Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology
Neurosurgery – December 08, 2022
Summary
Psychedelics like Psilocybin are profoundly re-emerging as potential medicine, showing promise for over a dozen neuropsychiatric conditions including severe Mood and Anxiety disorders. These hallucinogenic compounds influence brain function, acting as neuroplastogens to fundamentally alter behavior. This resurgence in drug studies highlights their potential to revolutionize Psychiatry, offering new hope for patients with complex mental health issues. Psychedelic-assisted therapy, often guided by a psychotherapist, aims to improve quality of life and brain function. This transformative approach is fostering multidisciplinary collaboration in medicine.
Abstract
After a decades-long pause, psychedelics are again being intensely investigated for treating a wide range of neuropsychiatric ailments including de...
Distinctive Molecular and Metabolic Profiles of Chemically Synthesized Psilocybin and Psychedelic Mushroom Extract
OpenAlex – July 20, 2023
Summary
Natural psilocybin mushroom extracts demonstrate superior brain benefits compared to synthetic versions. In male mice, a hallucinogen-rich mushroom extract significantly boosted four key synaptic proteins across four brain regions, indicating enhanced neuroplasticity, lasting 11 days. In contrast, chemically synthesized psilocybin showed more limited effects, impacting only two proteins in two areas. This suggests the full mushroom's complex chemistry, relevant to drug studies and chemical synthesis of alkaloids, offers a distinct neurotransmitter receptor influence on behavior. This difference is vital for understanding psychedelics.
Abstract
Abstract Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatri...
Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential
Proceedings of the National Academy of Sciences – April 14, 2025
Summary
Neuroscience offers hope for disorders. Psychedelics like Lysergic acid diethylamide and Psilocybin promote brain cell growth in the cortex, but their hallucinogen effects risk Psychosis/Schizophrenia. Through chemical synthesis, a new alkaloid (+)-JRT emerged. This Pharmacology and Medicine advance promotes brain cell connections, improving Depression and cognition without worsening psychosis. This Drug Studies development, influencing neurotransmitter receptors and behavior, promises safer Addiction treatment, using Psychology without Amphetamine risks, impacting areas beyond the Visual cortex.
Abstract
Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and sch...
Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain.
Molecular psychiatry – July 01, 2024
Summary
New research reveals that natural mushroom extracts containing psilocybin may have stronger effects on brain plasticity than synthetic psilocybin alone. Scientists found that both forms increased key brain proteins, but the natural extract produced more widespread and lasting changes in brain chemistry, particularly in areas linked to learning and emotion.
Abstract
Psilocybin, a naturally occurring, tryptamine alkaloid prodrug, is currently being investigated for the treatment of a range of psychiatric disorde...
Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress
Translational Psychiatry – June 14, 2025
Summary
Psilocybin, a potent hallucinogen, significantly reversed depressive and anxiolytic-like behaviors caused by chronic stress in an animal model. Two 1 mg/kg doses revealed neurochemical changes, boosting serotonin-2A-receptors—key for neurotransmitter receptor influence on behavior—and increasing glucocorticoid-receptor expression. This Neuroscience and Psychology research, relevant for Medicine and Psychiatry, suggests psilocybin's potential. A psychotherapist might consider these insights from Psychedelics and Drug Studies, understanding how this tryptophan-derived compound modulates brain disorders.
Abstract
Abstract Depression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available tr...
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology – June 15, 2025
Summary
Psychedelics are revolutionizing Psychiatry. Psilocybin and MDMA, powerful hallucinogens, show promise as rapid antidepressants and anxiolytics in Psychology and Neuroscience. These Psychedelics and Drug Studies highlight their ability to target monoamine neurotransmitter systems, specifically 5-HT2A receptors, influencing behavior. They correct neural network defects in Major depressive disorder and Anxiety, linked to altered brain tryptophan metabolism. Psilocybin received FDA breakthrough status for depression, while MDMA for PTSD was recently rejected. This offers new hope for severe mental health conditions.
Abstract
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin...
Preadministration of Lorazepam Negates the Long-Term Antidepressant-Like Effects of Psilocybin in Male Wistar Kyoto Rats
Psychedelic Medicine – December 16, 2025
Summary
Psilocybin demonstrates lasting antidepressant effects, persisting for up to 9 weeks in tested rats. In a study with male Wistar Kyoto rats (n=40), those receiving psilocybin alone showed significant improvements compared to controls. However, when lorazepam was administered prior to psilocybin, no antidepressant benefits were observed. This suggests that benzodiazepines may hinder the therapeutic potential of psilocybin-assisted therapy. Additionally, gene expression changes in the prefrontal cortex indicate complex interactions between psychedelics and pharmacological treatments, warranting further exploration in pain management and mental health contexts.
Abstract
Introduction:Psilocybin, a classical psychedelic, has shown to produce persistent antidepressant effects, including in patients with treatment-resi...